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Direct reprogramming of somatic cells into pluripotent cells by retrovirus-mediated expression of OCT4, SOX2, KLF4, and C-
MYC is a promising approach to derive disease-speciﬁc induced pluripotent stem cells (iPSCs). In this study, we focused on
three murine models for metabolic liver disorders: the copper storage disorder Wilson’s disease (toxic-milk mice), tyrosinemia
type 1 (fumarylacetoacetate-hydrolase deﬁciency, FAH−/− mice), and alpha1-antitrypsin deﬁciency (PiZ mice). Colonies of iPSCs
emerged 2-3 weeks after transduction of ﬁbroblasts, prepared from each mouse strain, and were maintained as individual iPSC
lines. RT-PCR and immunoﬂuorescence analyses demonstrated the expression of endogenous pluripotency markers. Hepatic
precursor cells could be derived from these disease-speciﬁc iPSCs applying an in vitro diﬀerentiation protocol and could be
visualized after transduction of a lentiviral albumin-GFP reporter construct. Functional characterization of these cells allowed
the recapitulation of the disease phenotype for further studies of underlying molecular mechanisms of the respective disease.
1.Introduction
To date, more than 200 liver-based defects are identiﬁed,
which can cause hepatic and extrahepatic diseases, and
such inborn errors of liver metabolism account for 15%
to 20% of liver transplantation indications for children.
Hence, the elucidation of the molecular pathways of liver
regeneration and extensive preclinical cell transplantation
experiments in animals have led to the application of
hepatocyte transplantation in a number of patients with
hereditary metabolic liver disease and acute liver failure [1–
4]. In these ﬁrst clinical studies, hepatocyte transplantation
has been considered either as a full-treatment option, or,
in more severe situations as a bridge to transplantation [5].
Furthermore, it was shown that cryopreserved hepatic cells
from one organ could be applied for multiple children [6].
The generation of iPS cells from adult somatic cells by
retrovirus-mediated expression of pluripotency-associated
genes in mice [7–10] and in humans [11–13]o ﬀers a unique
tool to generate disease-speciﬁc iPS cells for pathophysi-
ological studies (Figure 1). As a proof-of-principle, it was
demonstrated in recent publications that iPS cells from a
murine sickle cell anaemia model as well as from Fanconi
Anaemia patients can be generated, repaired, and used for
the correction of the disease by transplantation [14, 15].
However, in order to use those iPS derivatives for studies
of the disease, suitable diﬀerentiation protocols need to be
applied to get a disease-speciﬁc cell phenotype. In the past,
we and others have generated hepatic precursor cells from
human and mouse embryonic stem-cell lines [16–19]. With
the existing diﬀerentiation protocols, a primitive hepatic
phenotype with foetal gene expression patterns can be
induced in the majority of the embryonic stem cells [16, 20].
Transplantation of these cells, however, have so far resulted
only in scattered formation of hepatocytes or were reported
to form small hepatocyte clusters in major urinary pro-
tein promoter- (Mup-) driven urokinase-type plasminogen
activator (uPA) and FAH−/− mice [21–23]. Nevertheless,
hepatic cells suitable for pharmacological testing have been
described [24], and in a more recent publication, hepatic cell
diﬀerentiation of human ES cells was reﬁned [25] achieving2 Stem Cells International
Figure 1: iPS cells as model to study metabolic liver diseases.
Induced pluripotent stem cells (iPSCs) can be generated using
retro- or lentiviral constructs expressing the canonical repro-
gramming factors Oct4, Klf4, and Sox2 with or without c-Myc.
This technique allows the generation of pluripotent stem cells
from diseased individuals. Subjection of these iPS cells to hepatic
diﬀerentiation protocols results in an easily accessible source of
disease-speciﬁc hepatic cells. Importantly, this technique might
pave the way for in depth study of corresponding liver diseases.
transplantable hepatic cells, which functionally engrafted in
livers of immunodeﬁcient mice.
In our studies, we aimed on generating disease-speciﬁc
iPS cell from mice carrying genetic defects for three clinically
relevant metabolic liver diseases. As murine model of the
copper storage disorder Wilson’s disease, we chose the so-
called toxic milk mice, which carry a point mutation in the
ATP7b gene [26] and closely represent the disease phenotype
in patients [27]. As model for acute tyrosinemia type I, we
studied fumarylacetoacetate hydrolase-deﬁcient (FAH−/−)
mice [28], which also serve as a well established liver regen-
eration model for studies on hepatic cell transplantation
mechanisms. Finally, we investigated a transgenic mouse
strain, which expresses the mutated isoform of the human
α1-antitrypsin variant (PIZ) and which depicts liver damage
related to accumulation of the misfolded proteins [29].
2.MaterialsandMethods
2.1. Mice, Animal Tissue Samples, and Cell Sources.
C3HeB/FeJ-Atp7btx-J/J (common name: toxic-milk mice)
were obtained from Jackson Lab (Bar Harbor, Me, USA).
FAH−/−-mice were provided by Arndt Vogel (Hannover
Medical School, Germany), and tissue samples (ear cuts
and tail tips) from adult PiZ mice were obtained from
Robert Bals (University of Homburg/Saar, Germany). All
animals were maintained and handled in accordance with
institutional guidelines with free access to food and water.
Murine embryonic stem cells carrying an Oct4 promoter-
driveneGFPtransgenederivedfromOG2mice[30]aswellas
embryonicstemcellsderivedfromC3Hmice(CharlesRiver)
were provided by the Max Planck Institute for Molecular
Biomedicine (M¨ unster, Germany).
2.2. Isolation and Reprogramming of Adult Mouse Fibroblasts.
Fibroblasts were isolated foetuses of toxic-milk and FAH−/−
mice (ED 13.5) and ear cuts of adult PiZ mice, respectively.
Cells were maintained in DMEM low glucose (PAA, Austria)
suppliedwith10%FBS(PAA),1%Penicillin/Streptomycin+
L-Glutamine (PAA) and 100μM β-Mercaptoethanol (Gibco,
Germany). One day before transduction, ﬁbroblasts were
seeded at 100,000 cells per well of a 6-well plate (TPP,
Switzerland). Next day, toxic-milk and FAH−/− ﬁbroblasts
were transduced with 3μL each of concentrated retroviral
r e p r o g r a m m i n gv e c t o r sh O C T 4 ,h S O X 2 ,h K L F 4 ,a n dh C -
MYC,whereasPiZﬁbroblastsweretransducedwith3μLeach
of concentrated lentviral hOCT4, hSOX2, and hKLF4. Cells
were cultured for 24 days in mouse ES cell medium supple-
mented with leukemia inhibitory factor (LIF) and replated
on a 6cm dish of C3H mouse embryonic ﬁbroblast (MEF)
feeder cells. 6 days later, colonies were picked and subcloned.
2.3. Production of Lentiviral and Gamma-Retroviral Vectors.
For lentiviral vectors production, one day before trans-
fection, HEK 293T cells were seeded at 3 × 106 cells
per 10cm dish (TPP) in DMEM complete (DMEM high
glucose, PAA) supplied with 10% FBS (PAA) and 1%
Penicillin/Streptomycin + L-Glutamine (PAA). On the day
of transfection, medium was exchanged with 8mL DMEM
complete supplemented with 25μM Chloroquine (Sigma-
Aldrich, Germany). Plasmids encoding for lentiviral gag/pol
(pCDNA3.GP.CCCC, 10μg), RSV-Rev (pRSV-Rev, 5μg),
VSV-G (pMD2.G, 2μg), and packaging plasmid encoding
forrespectivetransgene(SFFV-hOCT4,SFFV-hSOX2,SFFV-
hKLF4, SFFV-hC-MYC, and Alb-GFP, 10μg) were mixed
in 400μL of ddH2O and 100μLo f1 . 2 5 MC a C l 2.T h e
plasmids-CaCl2 mixture was added dropwise to 2xHBS and
observed until precipitates became visible in phase-contrast
microscope and then added to HEK cells. 7 hours later,
medium was exchanged with 10mL DMEM complete, and
36 hours later, supernatant was collected, passed through
0.45μm ﬁlter, and centrifuged at 14,000×gf o r8 h .V i r u s
pellet was resuspended in PBS (PAA) in 0.5% of volume
of collected supernatant (200-fold concentration). Gamma-
retroviral vectors were produced as previously reported [31].
2.4. Pluripotent Stem-Cell Culture. Murine iPSC and OG2
(Oct4-GFP transgenic) embryonic stem (ES) cells were
cultivated on mouse embryonic ﬁbroblasts on gelatinized
dishes (Falcon BD) in culture medium I (Knock Out
DMEM, Invitrogen) supplemented with 15% FCS (selected
batches) and additives: 0.2% 50mM β-Mercaptoethanol, 1%
Pen/Strep/L-Gln, 1% nonessential amino acids (all PAA) and
10ng/mL recombinant human leukemia inhibitory factor
(LIF, Chemicon).
2.5. Immunocytochemistry. Cells were seeded on C3H feeder
cells three days prior to cytochemistry staining at a density
of 50 cells per well in a 24-well dish (TPP). Cells were ﬁxed
with 4% PFA for 20min at 4◦C, washed twice with TBS,
and permeabilized with 0.1% Tween 20 and 0.05% NP-40
in TBS for 30min at room temperature (RT). Fixed cells
were blocked with 5% BSA in TBS for 30min at RT, and
washed three times with TBS. Primary antibody was diluted
in TBS 1:75 for Nanog (Santa Cruz, sc-30328) and 1:100
for Oct4 (Santa Cruz, sc-5279), incubated for 1h at RT and
washed three times. Secondary antibody was diluted 1:400
in TBS (Invitrogen: Nanog Alexa Fluor 647A21447 and for
Oct4 Alexa Fluor 488 A11001) and incubated for 45min
at RT. Cells were washed twice and stained with 0.2μg/mL
DAPI (Invitrogen D3571) in TBS for 1min at RT. Cells wereStem Cells International 3
washed twice and analysed using Olympus IX71 and Cell P
software.
2.6.AlkalinePhosphatase(AP)Staining. APstainingwasper-
formed using the Chemicon Alkaline Phosphatase Detection
Kit (Millipore, USA) according to manufacturer’s protocol.
2.7. cDNA Synthesis and Taqman-Based qRT PCR. cDNA
synthesis was performed using the SuperScriptTM III First-
Strand Synthesis System for RT-PCR Kit (Invitrogen, USA)
with Random Hexamers. Taqman-based qRT PCR assays
were performed on the StepOne Plus Cycler (Applied
Biosystems) using the standard settings. Taqman probes
were ordered from Applied Biosystems for murine β-
Actin (Mm00607939 s1), Oct4 (Mm00658129 gH),
Sox2 (Mm00488369 s1), Nanog (Mm02019550 s1),
Albumin (Mm00802090 m1), Afp (Mm00431715 m1),
Ck18 (Mm01601706 g1), Abcc2 (Mm00496899 m1), Ttr
(Mm00443267 m1), Hnf4a (Mm00433964 m1) and human
SERPINA1 (Hs01097800 m1), OCT4 (Hs 03005111 g1),
SOX2 (Hs 01053749 s1), KLF4 (Hs 00358836 m1),
and C-MYC (Hs 01570247 m1). Analyses of exogenous
retrovirally expressed murine reprogramming was
performed using the following primer/probe combinations:
pMXs-Oct4 for:TGGTACGGGAAATCACAAGTTTG,
rev:GTCATAGTTC CTGT TGGTGA AGTTCA,
probe:6FAM-CTTCACCATGCCCCTCA-MGB;pMXs-
So x2for:GTGTGGTGGTACGGGAAATCAC,r ev:
TTCAGCTCCGT CTCC ATCATG,probe:6FAM-
TGTACAAAAAAGCAGGCTTGT-MGB; pMXs-Klf4 for:
GTGTGGTGGTACGGGAAATCA, rev: CGCGAACGTGG-
AGAA GGA, probe: 6FAM-CTTCACCATGGCTGTCAG-
MGB; pMXs-cMyc for: TGGTACGGGAAATCACAAGTT-
TG, rev: GTCATAGTTCCTGTTGGTGAAGTTCA, probe:
6FAM-CTTCACCATGCCCCTCA-MGB.
2.8.TeratomaAssays. Forteratomaformationassays,1 ×106
cells were transplanted subcutaneously into NOD/SCID
mice and grown for 2-3 months. Mice were sacriﬁced, and
teratomas were ﬁxed in 10% formalin and embedded into
paraﬃn. Sections were stained with Hematoxylin and Eosin
and evaluated for the formation of the three germ layers.
2.9. Hepatic Diﬀerentiation Protocol. iPSCs were diﬀerenti-
ated with a modiﬁed version of the hanging drop method
as previously published by Kania et al. [17]. Brieﬂy, iPSCs
were trypsinized and preplated on gelatin-coated 6cm dishes
(TPP) for 45min for separation from feeder-cells. iPS cell
containingsupernatantswerecentrifugedat250×gfor4min
and resuspended in mouse ES cell culture medium without
LIF to 30000 cells/mL. From this cell suspension, 50 × 20μL
hanging drops were put on the inside of the lid of a 10cm
dish and grown at 37◦Ci n5 %C O 2 incubator for embryoid
body (EB) formation. At day 5, EBs were collected and
kept in IMDM with 20% FBS, 1% Pen/Strep/L-Gl n, 1%
nonessential amino acids, 0.2% 50mM β-Mercaptoethanol,
0.1% 450mM α-Monothioglycerol (all PAA) on gelatin-
coated 6-wells (25 EB’s per well). 9 days later, cells were
trypsinized and transferred on rat tail collagen type I-
(Roche Diagnostics) coated 6-wells and kept in IMDM for
overnight attachment. Next day, cells were washed once
with PBS and kept on HCM with SingleQuots (Lonza)
for further hepatic diﬀerentiation for 14–20 days. In case
of transduction with lentiviral Alb-GFP reporter construct,
1 × 10e6 lentiviral particles (MOI ∼ 3–5) were added to
2 m LH C Mi ne a c hw e l lo fa6 - w e l la td a y5+9+3a n d
incubated for 48h before medium exchange. This protocol
yields in transduction eﬃcacy close to 100% in murine
hepatoma cells (Hepa 1–6) with on negligible expression in
nonhepatic cells, such as ﬁbroblasts. Hepatic diﬀerentiation
eﬃciency was estimated by FACS analysis for GFP-positive
cells at the end of diﬀerentiation on a BD FACS Calibur (BD
Biosciences).
2.10. Albumin ELISA. Cell supernatant was harvested after
three days from day 5 + 9 + 14 hepatic diﬀerentiated cells.
Supernatant of Hepa 1–6 cells served as a positive control
and was diluted 1:1 with fresh media. The ELISA was per-
formedaccordingtomanufacturesprotocol(Mousealbumin
ELISA Kit; Bethyl Laboratories) using 100μL supernatant
per reaction. The primary antibody was diluted 1:1,000,
the secondary antibody 1:10,000 and TMB ELISA Sub-
strate was added (Thermo Scientiﬁc Pierce, USA). Secreted
albumin was calculated per 1,000 cells and normalized to
time.
2.11. Urea Production. Urea production was analysed using
the diacetyl monoxime method [32]. Supernatant was
harvested after three days from day 5 + 9 + 14 hepatic
diﬀerentiated cells. For the colour reaction, 100μLs u p e r -
natant was mixed with 1400μL reagent (distilled water,
mixed acid reagent, and mixed colour reagent in the ratio
1:1:1) and boiled for 15min at 98 ◦C. Absorbance was
detected using a 540nm ﬁlter in a single point mea-
surement. The results were normalized 10,000 cells and
24h.
2.12. Cytochrome P450 Activity. Activation of cytochrome
P450 subtype 1A1 was determined using the EROD assay
[33]. Fresh media containing 10μM dicumarol and 8μM7 -
ethoxyresoruﬁn was added for two hours on day 5 + 9 +
14 hepatic diﬀerentiated cells. 75μL of cell supernatant was
mixed with 25μL 0.1M Na-Ac solution and incubated with
10 units of β-glucuronidase/arylsulfatase for 2h at 39◦C.
Reactionwasstoppedbyadding200μLEtOH,andresorfurin
was analysed photometrically using 535nm excitation and
595nm emission ﬁlters. Results were normalized to 10,000
cells and 2h.
2.13. Karyotype Analysis. Cells were treated with 10μm/mL
Nocodazole for 8 hours to arrest cells in metaphase. These
cells were then collected after trypsinization and lysed in
0.56% KCl before ﬁxation in methanol:acetic acid (3:1).
The cell nuclei were then dropped on glass slides from a
height of 1.5 meters and further stained with DAPI for
chromosomal count analysis.4 Stem Cells International
3. Results andDiscussion
3.1. iPSC from the Murine Model of Wilson’s Disease. As
ﬁrst murine model of hepatic liver diseases, from which we
generated iPSCs, we chose Jackson toxic-milk mice. These
mice reﬂect the human disorder Wilson’s disease leading to
ﬁbrotic changes, inﬂammatory inﬁltration, and copper accu-
mulation in the mice’s liver [27]. Toxic-milk mice-derived
iPSCs were generated using foetal ﬁbroblasts cultured under
adherent monolayer conditions. Cells were transduced with
gamma-retroviruses encoding for the mouse Oct4, Sox2,
Klf4, and c-Myc cDNAs [7, 31] and maintained under
normal feeder cell culture conditions. After six days, the
transduced cells were split and seeded on irradiated feeder
cells applying standard mouse embryonic stem-cell culture
conditions. About two weeks later colonies with diﬀer-
ent morphologies emerged from the initially transduced
cells (Figure 2(a)). Those colonies, which morphologically
most closely resembled normal embryonic stem cells, were
mechanically picked and subcloned, prior to further culti-
vation for derivation of individual iPSC lines (Figure 2(b)).
For further characterisation, the iPSCs were seeded on cover
slips for immunohistochemical staining (Figures 2(c)–2(f)).
Analyses of the two most important pluripotency-associated
markers Oct4 (Figure 2(c)) and Nanog (Figure 2(d)) clearly
depicted the colocalisation of these markers with the DAPI
stained nuclei (Figure 2(e)) of toxic-milk iPSC colonies.
Furthermore, the pluripotent status of the toxic-milk iPSC
colonieswasconﬁrmedbyalkalinephosphatase(AP)activity
as depicted in Figure 2(g), which is a functional hallmark
of reprogrammed pluripotent stem cells. Our ﬁndings were
further supported by quantitative analyses of the gene
expression proﬁle by qRT PCR (Figure 2(i)). The derived
toxic-milk iPSC line shows a high expression level of the
pluripotent markers Oct4, Nanog, and Sox2 referred to silent
transcriptional activity in the starting murine embryonic
ﬁbroblasts. Compared to control embryonic stem cells
(ESCs), derived from Oct4-GFP transgenic (OG2) mice, the
gene expression of these markers was slightly reduced, but
the proportions between the diﬀerent markers reﬂected the
expression pattern of murine embryonic stem cells. Toxic-
milk iPSCs were able to form teratomas when transplanted
subcutaneously into NOD/SCID mice (Figures 2(j)–2(l)),
and, moreover, the reprogramming transgenes were shown
to be silenced in the fully reprogrammed iPSCs (Sup-
plementary Figure 1(A) which is available online at doi:
10.4061/2011/924782). Karyotype analysis revealed a diploid
set of 40 chromosomes (Figure 2(h)). To summarise, our
toxic-milk iPSC line exhibited the most important pluripo-
tent stem cells’ characteristics suggesting a well-established
pluripotency network and a fully pluripotent status of these
reprogrammed cells.
For the hepatic diﬀerentiation of toxic-milk iPS cells
we used a protocol based on the generation of cell aggre-
gates in embryoid bodies [17, 21]. The embryoid bodies
were ﬁrst cultured in “hanging drops” and then plated in
media containing α-monothioglycerol supporting endoder-
mal speciﬁcation, before maturation in hepatocyte culture
medium (HCM), which supports diﬀerentiation of hepatic
precursorcells.Attheﬁnalstageofthisprotocol,weobtained
cells exhibiting a polygonal morphology, which resembled
deﬁnitive endoderm-derived hepatic cells (Figure 3(a)). For
furtheranalyses,thediﬀerentiatedcellsweretransducedwith
a lentiviral reporter construct expressing enhanced green
ﬂuorescent protein (eGFP) under transcriptional control of
the Albumin promoter/enhancer cassette [21]. This assay
identiﬁed the polygonal-shaped diﬀerentiated cells as eGFP-
expressing hepatic cells (Figure 3(b)) obtained at the ﬁnal
step of the diﬀerentiation protocol. However, the total
amount of eGFP-positive cells was below 10%, and, there-
fore, the putative hepatic cells were puriﬁed by ﬂuorescence-
activated cells sorting (FACS) prior to gene expression anal-
yses by quantitative RT-PCR (Figure 3(c)). The toxic-milk
iPSC-derivedhepaticcellsexpressedtheadulthepaticmarker
albumin (Alb), the progenitor marker α-fetoprotein (Afp),
cytokeratin 18 (Ck18), which is a marker distinguishing hep-
atic cells from cholangiocytic cells, transthyretin (Ttr), and
hepatocyte nuclear factor 4α (Hnf4α). Furthermore, expres-
sion of the apical conjugate export pump MRP2 (AbcC2)
was detectable, which is a hallmark of polarized hepatocytes,
exhibiting a (sinusoidal) basolateral and (canalicular) apical
membrane domain. Next, we applied 250μMc o p p e rs u l -
phate during the last 7 days of hepatic diﬀerentiation and
evaluated ATP7B-mediated copper transport in toxic-milk
iPSC-derived hepatic cells in comparison to hepatic cells
from controls (C3H mice-derived iPSCs). The number of
hepatic cells derived from the control C3H-iPSCs increased
1.8-fold when 250μM copper sulphate was added, due to the
toxic eﬀect of copper on nonhepatic cells in the bulk fraction
of diﬀerentiating cells (Figure 3(d)). Remarkably, hepatic
cells derived from the toxic-milk iPSCs were not protected
during the copper sulphate challenge, which conﬁrms the
ATB7B-deﬁcient phenotype of these cells.
3.2. iPSC From FAH-Deﬁcient Mice to Study Tyrosinemia
Type 1. As a second murine model of hereditary metabolic
liver diseases, we investigated fumarylacetoacetate hydrolase
knockout (FAH−/−)m i c e[ 28], which serve as a model for
acute tyrosinemia type 1, resulting in a lethal neonatal liver
dysfunction phenotype [34]. We have generated iPSCs from
these mice by transduction of FAH−/−-MEFs with retroviral
vectors encoding mouse Oct4, Sox2, Klf4, and c-Myc. 9–12
days after initial transduction ﬁrst iPSC-like colonies were
observed, which were subcloned as individual FAH−/−-iPSC
lines on day 16 (Figure 4(a)). The expression of endogenous
pluripotency markers in these reprogrammed cells was con-
ﬁrmedbyimmunoﬂuorescencestainingagainstmurineOct4
and Nanog (Figures 4(b) and 4(c)). Fully reprogrammed
FAH−/−-iPSCs cells showed eﬀective silencing of reprogram-
ming transgenes (Supplementary Figure 1(B)), retained a
normal karyotype (Figure 4(d)) and activated the endoge-
nous pluripotency network with strong expression of Oct4,
Nanog, and Sox2 (Figure 4(e)). Furthermore, 5 weeks after
subcutaneous injection of 1 × 106 undiﬀerentiated FAH−/−-
iPSCs into NOD/SCID mice we could analyse teratomas,
which contained various cell types from all three germ
layers as depicted in Figures 4(f)-4(g). Next, we appliedStem Cells International 5
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Figure 2: Generation & characterization of toxic milk iPS cells. (a) iPSCs generated from ﬁbroblasts isolated from toxic-milk mice using
retroviral vectors expressing human OCT4, KLF4, SOX2 and c-MYC. (b) iPSCs were subcloned to obtain better colony morphology. (c)–(f)
Subcloned iPSCs stained positive for murine Oct4 and Nanog, whilst DAPI was used to stain the nuclei. (g) Staining for alkaline phosphatase
expression of toxic-milk iPSC subclones. (h) Karyotype analysis of DAPI stained metaphase spreads. (i) qRT PCR analysis for endogenous
Oct4, Nanog and Sox2 expression in toxic-milk iPSCs and OG2 ESCs compared to mouse embryonic stem cells. (j)–(l) Teratoma sections
depicting formation of neuroectoderm, mesoderm (connective tissue), and endoderm.6 Stem Cells International
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Figure 3: Hepatic diﬀerentiation of toxic milk iPS cells. (a, b) Toxic-milk iPS were subjected to hepatic diﬀerentiation using hanging drop
method and transduced with lentiviral Alb-GFP expression vector. (c) qRT PCR analysis for hepatic marker genes Afp, Alb, Ck18, Abcc2,
Ttr, and Hnf4α. Undiﬀerentiated cells served as negative control, in which no hepatic gene expression was determined until cycle 45 (↓).
(d) During the last seven days of diﬀerentiation, the cells were challenged with copper. The toxic-milk mice-derived cells could not export
copper, and, therefore, no enrichment of Alb-positive cells was achieved. However, C3H-derived control cells were able to “detoxify” copper
after hepatic speciﬁcations and, therefore, Alb-eGFP-positive cells were enriched.
the previously described hepatic in vitro diﬀerentiation
protocol also to the FAH−/−-iPSCs. After diﬀerentiation,
FAH−/−-iPSCs showed expression of a set of characteristic
hepatic markers (Afp, Alb, Ck18, AbcC2, Ttr, Hnf4) as
shown in Figure 4(i). The amount of hepatic cells derived
from the FAH−/−-iPSCs was estimated by the proportion
of eGFP-positive cells (Figures 4(j)-4(k)), at the end of the
diﬀerentiation period (day 5 + 9 + 20), three days after
transductionwiththelentiviralreporterconstructexpressing
eGFP driven by the Albumin promoter/enhancer [21].
Because neonatal FAH−/−-mice can be rescued from hepatic
failurebysupplementationwiththecompound2-(2-nitro-4-
triﬂuoromethylbenzoyl)-1,3 cyclohexanedione (NTBC) we
also added this substance during the last 10 days of the in
vitro diﬀerentiation protocol to a subset of our experiments
(Figures 4(l)-4(m)). Fluorescence microscopy at the end
of the diﬀerentiation protocol revealed that the treatment
with 20μg/mL of NTBC supports the viability of hepatic
cells derived from FAH−/−-iPSCs, as we could observe a
higher proportion of Alb-eGFPpos cells in the diﬀerentiated
population of cells receiving NTBC (Figure 4(l)) compared
to diﬀerentiated cells from untreated cells (Figure 4(j)).
3.3. PiZ Mice-Derived iPSCs for Studying α1-Antitrypsin Deﬁ-
ciency. As a third murine model of a hereditary metabolic
liver disease, we investigated PiZ-mice, which express a
mutated form of human α1-antitrypsin and acquire a
human disease-speciﬁc liver phenotype [27, 29]. The PiZ
α1-antitrypsin protein corresponds to a point-mutation
(E342K) in the human SERPINA1 gene [35] and is termed
proteinase inhibitor Z-variant or PiZ, which is prone
to polymerization and accumulation in the endoplasmic
reticulum of hepatocytes and can lead to liver cirrhosis
and hepatocarcinoma [36]. To generate iPSCs from suchStem Cells International 7
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Figure 4: FAH−/−-iPS cells. (a)–(c) iPS generated from ﬁbroblasts isolated from FAH−/−-mice using retroviral vectors expressing human
OCT4, KLF4, SOX2, and c-MYC were stained for murine Nanog and Oct4. (d) Karyotype analysis of DAPI stained metaphase spreads.
(e) Expression of endogenous Oct4, Nanog, and Sox2 determined by qRT PCR compared to ES cells. (f)–(h) FAH−/−-iPSCs were able to
form tissues from all three germ layers when transplanted subcutaneously into NOD/SCID mice. (i) qRT PCR analysis for hepatic marker
genes Afp, Alb, Ck18, Abcc2, Ttr, and Hnf4α. Undiﬀerentiated cells served as negative control, in which no hepatic gene expression was
determined until cycle 45 (↓). (j)-(k) FAH−/−-iPSCs diﬀerentiated using the hanging drop method and transduced with lentiviral Alb-eGFP
expression vector. (l)-(m) FAH−/−-iPSCs diﬀerentiated with the same method but with NTBC treatment. The NTBC-treatment rescued the
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PiZ mice, we transduced ear ﬁbroblasts from PiZ-mice
with lentiviral vectors encoding human OCT4, SOX2, and
KLF4, respectively. 14 days after transduction iPSC-like
colonies were picked and subcloned to derive individual
PiZ-iPSC lines. These iPSCs depicted all morphological
features of murine pluripotent stem cells (Figure 5(a)) with
a compact colony shape and a clear shining borderline
to the surrounding feeder cells. Moreover, PiZ-iPS cells
stained positive for alkaline phosphatase (Figure 5(b)) and
possess a diploid karyotype consisting of 40 chromosomes
(Figure 5(c)). The characteristic gene expression of endoge-
nous pluripotency markers Oct4, Nanog and Sox2 was in
the same range as control murine embryonic stem cells
(Figure 5(d)),whereasexogenoushumanOCT4wassilenced
when compared to freshly transduced PiZ ear ﬁbroblasts
(Supplementary Figure 1(C)). Pluripotency of these PiZ-
iPSCs was further conﬁrmed by teratoma formation after
subcutaneous injection into NOD/SCID mice resulting in
tumours with various cell types of all three germ lay-
ers (Figures 5(e)–5(g)). Finally, we investigated if hepatic
derivatives of PiZ-iPSCs express the mutated human α1-
antitrypsin variant. To this end, we subjected PiZ-iPSCs
to our hepatic diﬀerentiation protocol. At day 5 + 9 + 3
after the start of diﬀerentiation, we transduced the cells
using our lentiviral Alb-eGFP-expressing reporter construct,
and we could observe morphologically distinct clusters of8 Stem Cells International
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eGFP-positive hepatic cells derived from diﬀerentiated PiZ-
i P S C so nd a y5+9+1 4( F i g u r e s5(j)-5(k)). Diﬀerentiated
and transduced cells were also analyzed by ﬂow cytometry
for Alb-GFP positive cells on day 5+9+14 (Figure 5(l))
demonstrating that the majority of cells (65.3%) exhibited
a hepatic phenotype. When we applied Taqman-based qRT
PCR analysis to these hepatic PiZ-iPSC-derivatives, we
were able to conﬁrm the hepatic phenotype by showing
expression of a set of characteristic hepatic markers, such as
Afp, Alb, Ck18, AbcC2, Ttr, Hnf4 (Figure 5(h)), and, more
importantly, we detected expression of the disease-causing
PiZ variant of the human SERPINA1 transgene, which was
as strong as albumin expression (Figure 5(m)). Functionality
of diﬀerentiated PiZ iPSCs was characterized by measuring
albumin secretion by ELISA, urea production, and CYP450
activity (Figure 5(i)).
Combining two recent breakthroughs in stem-cell biol-
ogy, the generation of patient-derived pluripotent stem cells
[37] and the generation of hepatic cells from uncommitted
pluripotent stem cells [16, 18–20, 25], new therapeutic
approaches for various metabolic liver diseases may emerge.
With respect to metabolic liver diseases, two recent publi-
cations support the feasibility of generating such disease-
speciﬁc iPS cells from murine [38] and human individuals
[39]. Those cellsoﬀer a unique opportunity for studies of the
pathophysiology of the respective disease on a cellular level.
To this end, we investigated whether hepatic progenitors
depicting the pathophysiological hallmarks of the respective
disease can be generated from iPSCs derived from murine
models of the copper storage disorders Wilson’s disease
[26], of acute tyrosinemia type I [28], and of α1-antitrypsin
deﬁciency [29]. All three murine disease models cover the
relevant characteristics of the hepatic disease phenotypes in
patients and were well-studied animal models.
Although recent publications suggest alternative app-
roaches for iPSC generation such as use of nonintegrating
viral vectors [40–43], protein transduction [44, 45], plasmid
transfection [46], or stabilized mRNA application [47], we
chose the well-established gamma-retroviral vector system
[7, 31] for delivery of the reprogramming factors to MEFs
from toxic-milk mice and FAH−/−-mice and a recently
improved lentiviral delivery system for iPSC generation from
PiZ-mouseﬁbroblasts[48].Inthelightofrecentpublications
discriminating between partially and fully reprogrammed
iPSCs and diﬀerences in the epigenetic memory in iPSCs
[49–51], we assume that the robust viral delivery method is
the most stable reprogramming system. This conclusion is
supportedbythefactthatfullyiPSC-derivedmiceweresofar
only generated using iPSCs derived by these viral techniques
for complementation of nondeveloping tetraploid embryos
[49, 52–54]. The molecular and functional data from our
experiments provides strong evidence that our iPSC from
the various disease models are fully reprogrammed as we
observed a stable ES-like morphology for multiple passages,
strong expression of pluripotency markers and, most impor-
tantly, unimpaired diﬀerentiation capabilities into hepatic
cells, applying in vitro diﬀerentiation protocols.
Even if the embryoid body-based hepatic diﬀerentiation
protocol [17, 21] does not use the extrinsic supplementation
of instructive cytokines as Activin A or BMP4 for induction
of endodermal diﬀerentiation, we robustly obtained a pro-
portion of around 10% of the cells, which acquired a hepatic
phenotype. Furthermore, these cells functionally correlated
to the respective diseases, such as sensitivity to excess copper
administration in toxic-milk hepatic cells or response to
NTBCtreatmentinFAH−/−-hepatic cells. When we analyzed
the α1-antritrypsin related iPSCs from PiZ mice, we chose a
recently established cytokine-based diﬀerentiation protocol,
which is based on a monolayer cell culture in serum-free
media conditions [16]. Preliminary results suggested that the
hepatic cells obtained with this protocol are more mature,
but the overall reproducibility of this protocol needs further
attention. Most probably, the optimal cytokine application
schedule is strongly dependent on cell proliferation and
density as well as on other factors during the time course of
diﬀerentiation,and,therefore,therobustnessofthisprotocol
is not easy to achieve. Nevertheless, we chose this protocol
for the hepatic diﬀerentiation of PiZ-iPSCs, because we
aim to further elaborate on the α1-antitrypsin-deﬁency with
patient-derived iPSC in the future, which only is possible
with cytokine-based protocols acting on monolayer human
iPSC cultures.
4. Conclusions
Here, we successfully generated iPSC from three highly rele-
vant murine metabolic liver disease models, and we estab-
lished in vitro diﬀerentiation into disease-speciﬁc hepatic
cells, which exhibit the pathophysiological phenotype of the
clinical condition. Such cells will allow future studies on
new drug targets or gene repair strategies for the respective
metabolic liver disorder.
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